Penumbra Inc has achieved notable top-line growth over recent years primarily through its specialized thrombectomy and embolization medical devices. The company reported revenues of $1.4 billion in 2025, representing a 17.5% increase year-over-year, supported by robust sales of its aspiration and computer assisted vacuum thrombectomy technologies. However, profitability experienced volatility due to a strategic business exit and merger-related distractions. Penumbra’s ongoing merger with Boston Scientific introduces both synergies potential and substantial execution risk in operational continuity, talent retention, and customer relationships. Regulatory complexities and competitive pressures from larger industry players remain structural challenges.